Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377491 | 0.93 | CNR1 (0.66) | CNR1PTGS2HPGDSCNR2CYP2C9 | |
| SCHEMBL1381328 | 0.92 | CNR1 (0.78) | CNR1CNR2KCNH2SCN5ASCN2A | |
| SCHEMBL3844273 | 0.91 | CNR1 (0.80) | CNR1CNR2GPBAR1 | |
| SCHEMBL2704106 | 0.91 | CNR1 (0.80) | CNR1CNR2GPBAR1 | |
| SCHEMBL1377747 | 0.91 | CNR1 (0.64) | CNR1PTGS2CNR2CYP2C9MAPK14 | |
| SCHEMBL2704110 | 0.91 | CNR1 (0.80) | CNR1CNR2GPBAR1 | |
| SCHEMBL1377750 | 0.91 | CNR1 (0.64) | CNR1PTGS2CNR2CYP2C9MAPK14 | |
| SCHEMBL2704555 | 0.91 | CNR1 (0.64) | CNR1PTGS2CNR2CYP2C9MAPK14 | |
| SCHEMBL3924944 | 0.82 | CNR1 (0.45) | CNR1PTGS2HPGDSCNR2SCN10A | |
| SCHEMBL4013402 | 0.82 | CNR1 (0.64) | CNR1HPGDSCNR2KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4712865-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| EP-1868999-B1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | claimed |
| EP-1868999-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | claimed |
| US-7229999-B2 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-06-12 | — | — | US | claimed |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | claimed |
| WO-2006106054-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | claimed |
| EP-1868999-B1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-1868999-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| US-7229999-B2 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | disclosed |
| WO-2006106054-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | CNR1, CNR2, GPR119 | CNR1 1/4885PTGS2 2977/4885HPGDS 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.